Epidemiology and natural history of NAFLD and NASH.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Liver Disease

• Publication date

  2007-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLD.2007.02.009PMID 17544968
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Clinical Outcome of NAFLD Including Cryptogenic Cirrhosis

  2007cited by this paper
• The Epidemiology and Risk Factors of NASH

  2007cited by this paper
• LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis

  2006cited by this paper
• The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999–2002

  2006cited by this paper
• The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease

  2006cited by this paper
• Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease

  2005cited by this paper
• Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study

  2005cited by this paper
• Unexplained Elevations in Alanine Aminotransferase in Individuals with the Metabolic Syndrome: Results from the Third National Health and Nutrition Survey (NHANES III)

  2005cited by this paper
• Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients

  2005cited by this paper
• Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study

  2005cited by this paper
• The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

  2005cited by this paper
• Prevalence of and risk factors for fatty liver in a general population of Shanghai, China.

  2005cited by this paper
• Chronological development of elevated aminotransferases in a nonalcoholic population

  2005cited by this paper
• Circulatory dysfunction in NAFLD — Which is first, which is last, and what do we do in between?

  2005cited by this paper
• Approach to the diagnosis and treatment of nonalcoholic fatty liver disease.

  2005cited by this paper
• Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease

  2005cited by this paper
• The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

  2005cited by this paper
• Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease

  2005cited by this paper
• Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy.

  2004cited by this paper
• Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies

  2004cited by this paper
• Long term prognosis of fatty liver: risk of chronic liver disease and death

  2004cited by this paper
• Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.

  2004cited by this paper
• Fatty liver disease: NASH and related disorders

  2004cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

  2004cited by this paper
• Non‐alcoholic fatty liver disease – a common and benign finding in octogenarian patients

  2004cited by this paper
• Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C

  2003cited by this paper
• Nonalcoholic fatty liver disease (NAFLD)--two decades later: are we smarter about its natural history?

  2003cited by this paper
• Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey.

  2003cited by this paper
• Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

  2003cited by this paper
• The prevalence and etiology of elevated aminotransferase levels in the United States

  2003cited by this paper
• Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study.

  2003cited by this paper
• Nonalcoholic fatty liver disease (NAFLD) two decades later: are we smarter about its natural history?

  2003cited by this paper
• Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

  2003cited by this paper
• Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

  2003cited by this paper
• Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.

  2003cited by this paper
• The natural history of nonalcoholic fatty liver disease: a clinical histopathological study

  2003cited by this paper
• Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background

  2003cited by this paper
• Fatty liver in non‐alcoholic non‐overweight Japanese adults: Incidence and clinical characteristics

  2002cited by this paper
• NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States

  2002cited by this paper
• The utility of radiological imaging in nonalcoholic fatty liver disease.

  2002cited by this paper
• Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?

  2002cited by this paper
• Is NASH underdiagnosed among African Americans?

  2002cited by this paper
• Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.

  2002cited by this paper
• Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels

  2002cited by this paper
• Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association

  2002cited by this paper
• NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

  2002cited by this paper
• Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis

  2002cited by this paper
• Nonalcoholic fatty liver disease.

  2002cited by this paper
• Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

  2002cited by this paper
• Pathogenesis of steatohepatitis.

  2002cited by this paper
• Epidemiology of Fatty Liver in a Hospital-based Study in Taiwan

  2002cited by this paper
• Is NASH underdiagnosed among African Americans

  2002cited by this paper
• Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease

  2001cited by this paper
• Hepatocellular carcinoma arising in non‐alcoholic steatohepatitis

  2001cited by this paper
• Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease

  2001cited by this paper
• Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

  2001cited by this paper
• Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes

  2001cited by this paper
• Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology.

  2001cited by this paper
• Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

  2001cited by this paper
• Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis?

  2001cited by this paper
• High prevalence of NASH among Mexican American females with type II diabetes mellitus

  2001cited by this paper
• Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study

  2000cited by this paper
• Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?

  2000cited by this paper
• Association of nonalcoholic fatty liver disease with insulin resistance.

  1999cited by this paper
• Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients

  1999cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• Non-alcoholic fatty liver: another feature of the metabolic syndrome?

  1999cited by this paper
• Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease

  1999cited by this paper
• Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis

  1999cited by this paper
• Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient.

  1997cited by this paper
• Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation.

  1997cited by this paper
• Recurrence of nonalcoholic steatohepatitis following liver transplantation.

  1996cited by this paper
• The natural history of nonalcoholic fatty liver: A follow‐up study

  1995cited by this paper
• Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis

  1992cited by this paper
• The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years

  1990cited by this paper
• Nonalcoholic steatohepatitis: a study of 49 patients.

  1989cited by this paper
• Prevalence of fatty liver in a general population of Okinawa, Japan.

  1988cited by this paper
• Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury.

  1988cited by this paper
• Liver pathology in aircrew.

  1982cited by this paper
• Liver pathology in aircrew.

  1982cited by this paper
• Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

  1980cited by this paper
• Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties.

  1977cited by this paper

• Convergent Metabolic Pathways in MASH Therapeutics: An AMPK‐Centric Analysis

  2026cites this paper
• Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases.

  2026cites this paper
• Global, regional, and national burden of nonalcoholic fatty liver disease among adults aged ≥ 45 years: A comprehensive analysis of epidemiological trends and projections to 2035.

  2026cites this paper
• Chronic high‐fat diet induces multi‐organ dysfunction and metabolic homeostasis disruption in Macaca fascicularis

  2026influential citation
• In Vitro, In Vivo, and In Silico Investigation of Synbiotic-Mediated Activation of PPAR-α Curtails Nonalcoholic Steatohepatitis (NASH) in Wistar Rats by Inhibiting PNPLA3/SREBP1-c Lead Inflammatory Injury of Hepatic Cells

  2025cites this paper
• The effect of eight weeks of high-intensity interval training combined with L-citrulline malate supplementation on muscle damage, inflammation and physical fitness factors of volleyball girls

  2025cites this paper
• Prevalence of non-alcoholic fatty liver disease among inflammatory bowel disease patients: a systematic review and meta-analysis

  2025cites this paper
• Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective

  2025cites this paper
• The use of simple tests to predict biopsy-proven steatohepatitis in people with type 2 diabetes

  2025cites this paper
• Silkworm pupa powder alleviates metabolic dysfunction-associated steatotic liver disease by regulating microbial-intestinal-liver axis and TLR4 / MyD88 / NF-κB signaling pathway

  2025cites this paper
• PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis

  2025cites this paper
• Study of Serum Levels of CRP & its Relation to Asymptomatic and Incidentally Detected Fatty Liver Disease

  2024cites this paper
• Time Trends in Liver-Related Mortality in People With and Without Diabetes: Results From a Population-Based Study

  2024cites this paper
• Biomarkers of Hepatic Toxicity: An Overview

  2024cites this paper
• Differential diagnostic value of serum leptin level and polymorphism of the leptin receptor gene Gln223Arg in metabolic fatty and alcoholic liver diseases

  2024cites this paper
• Post-Liver Transplant Metabolic Syndrome.

  2024cites this paper
• Toxicity and Hepatoprotective Effects of ZnO Nanoparticles on Normal and High-Fat Diet-Fed Rat Livers: Mechanism of Action

  2024cites this paper
• Liver Fibrosis and Cirrhosis in Patients with Non-alcoholic Fatty Liver with and without History of Cholecystectomy: A Pilot Study

  2024cites this paper
• Air pollution exposure and prevalence of non-alcoholic fatty liver disease and related cirrhosis: A systematic review and meta-analysis.

  2024cites this paper
• Lipidomic and transcriptomic profiles provide new insights into the triacylglycerol and glucose handling capacities of the Arctic fox

  2024cites this paper
• The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• A population-based prospective study on obesity-related non-communicable diseases in northern Iran: rationale, study design, and baseline analysis

  2024influential citation
• Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease

  2023cites this paper
• The relationship between zonulin level and indicators of carbohydrate metabolism in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus

  2023cites this paper
• TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a “Prudent” Dietary Pattern on Serum Triglyceride Levels

  2023cites this paper
• Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury.

  2023cites this paper
• Evaluation of the Correlation between Coronary Artery Disease and Nonalcoholic Fatty Liver Disease: Is There Any Correlation?

  2023cites this paper
• The effect of melatonin, metformin and ursodeoxycholic acid on non-alcoholic fatty liver disease: A randomized, double-blinded controlled trial

  2023cites this paper
• Diagnostic efficiency on ultrasound shear wave elastography in evaluation of steatosis severity for non-alcoholic fatty liver disease: a rat model

  2023cites this paper
• Increased Expression of Hepatic Stearoyl-CoA Desaturase (SCD)-1 and Depletion of Eicosapentaenoic Acid (EPA) Content following Cytotoxic Cancer Therapy Are Reversed by Dietary Fish Oil

  2023cites this paper
• Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease

  2023cites this paper
• The role of moderate- and high-intensity supervised aerobic training in reducing steatosis and hepatic fibrosis in patients with non-alcoholic fatty liver disease; a randomized controlled trial

  2023cites this paper
• A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.

  2023cites this paper
• Influence of surgical treatment of obesity on the course of nonalcoholic fatty liver disease

  2023cites this paper
• The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease

  2022cites this paper
• [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].

  2022cites this paper
• Comparison of non-invasive imaging methods and laboratory findings on non-alcoholic fatty liver disease (NAFLD) in childhood

  2022cites this paper
• Serum Uric Acid but Not Ferritin Level Is Associated with Hepatic Fibrosis in Lean Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease: A Community-Based Study

  2022cites this paper
• The Safety and Effectiveness of a Polysaccharide Extracted from Rosa Canina in Patients with NAFLD: A Randomized Trial

  2022cites this paper
• Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis

  2022cites this paper
• The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial

  2022cites this paper
• Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic L

  2022cites this paper
• Diet Containing Soy Protein Concentrate With Low and High Isoflavones for 9 Weeks Protects Against Non-alcoholic Fatty Liver Steatosis Using Obese Zucker Rats

  2022cites this paper
• Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease

  2022cites this paper
• Polysaccharides and flavonoids from cyclocarya paliurus modulate gut microbiota and attenuate hepatic steatosis, hyperglycemia, and hyperlipidemia in nonalcoholic fatty liver disease rats with type 2 diabetes mellitus

  2022cites this paper
• A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study

  2022cites this paper
• Bromelain activates the AMP-activated protein kinase-autophagy pathway to alleviate hepatic lipid accumulation

  2022cites this paper
• Relation of Dietary Patterns and Nutritional Profile to Hepatic Fibrosis in a Sample of Lebanese Non-Alcoholic Fatty Liver Disease Patients

  2022cites this paper
• The tetraspanin transmembrane protein CD53 mediates dyslipidemia and integrates inflammatory and metabolic signaling in hepatocytes

  2022cites this paper
• Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications

  2022cites this paper
• Truncated Milk Fat Globule-EGF-like Factor 8 Ameliorates Liver Fibrosis via Inhibition of Integrin-TGFβ Receptor Interaction

  2021cites this paper
• Racial differences in prevalence and severity of non-alcoholic fatty liver disease

  2021cites this paper
• Study of new energy-based noninvasive therapies for nonalcoholic fatty liver disease

  2021cites this paper
• Fontan-associated liver disease

  2021cites this paper
• INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"

  2021cites this paper
• Ketogenic Diet Enhances the Cholesterol Accumulation in Liver and Augments the Severity of CCl4 and TAA-Induced Liver Fibrosis in Mice

  2021cites this paper
• MicroRNA-29c Acting on FOS Plays a Significant Role in Nonalcoholic Steatohepatitis Through the Interleukin-17 Signaling Pathway

  2021cites this paper
• Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats

  2021cites this paper
• A network pharmacology approach: Inhibition of the NF-κB signaling pathway contributes to the NASH preventative effect of an Oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats.

  2021cites this paper
• Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: Role of iron-dependent pathways.

  2021cites this paper
• Disease progression modelling for economic evaluation in non-alcoholic fatty liver disease - a systematic review.

  2021cites this paper
• Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Association between bilirubin and nonalcoholic fatty liver disease in the non-obese Chinese population: a cross-sectional study

  2021cites this paper
• Assessment of the Association of HIV Infection with Hepatic Steatosis or Fibrosis: a Cross-sectional Case–Control Study

  2021cites this paper
• Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver

  2021cites this paper
• Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma.

  2021cites this paper
• Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis

  2020cites this paper
• Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery

  2020cites this paper
• Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality

  2020cites this paper
• Non-alcoholic fatty liver disease in patients infected with human immunodeficiency virus: a systematic review.

  2020cites this paper
• Therapeutic importance of garlic supplementation in the management of nonalcoholic fatty liver disease: A systematic review of preclinical studies

  2020cites this paper
• Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review

  2020cites this paper
• The Effects of Endoplasmic-Reticulum-Resident Selenoproteins in a Nonalcoholic Fatty Liver Disease Pig Model Induced by a High-Fat Diet

  2020cites this paper
• Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System.

  2020cites this paper
• Dietary Total Antioxidant Capacity and Risk of Non-Alcoholic Fatty Liver Disease: A Case‐Control Study

  2020cites this paper
• Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

  2020cites this paper
• Lactobacillus fermentum CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice.

  2020cites this paper
• Food Insecurity, Race, and Adolescent Non-Alcoholic Fatty Liver disease in NHANES 2001-06

  2020cites this paper
• Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis

  2020cites this paper
• Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score

  2020cites this paper
• Chemotherapy-associated liver injury in colorectal cancer

  2020cites this paper
• Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis

  2020cites this paper
• Pathology in Patients with Chronic Liver Disease: A Practical Approach to Liver Biopsy Interpretation in Patients with Acute and Chronic Liver Diseases.

  2020cites this paper
• Review on Non-alcoholic Fatty Liver Disease: Pathogenesis, Management and Treatment

  2020cites this paper
• Targeting the Liver-Brain Axis with Hop-Derived Flavonoids Improves Lipid Metabolism and Cognitive Performance in Mice.

  2020cites this paper
• The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter.

  2020cites this paper
• Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.

  2020cites this paper
• The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease

  2020cites this paper
• Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.

  2020cites this paper
• The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.

  2020cites this paper
• Sini powder ameliorates the inflammatory response in rats with stress-induced non-alcoholic fatty liver disease by inhibiting the nuclear factor kappa-B / pyrin domain-containing protein 3 pathway.

  2020cites this paper
• Are We Ready for Bariatric Surgery in a Liver Transplant Program? A Meta-Analysis

  2020cites this paper
• De novo and recurrent liver disease.

  2020cites this paper
• Association between dietary sodium intake and non-alcoholic fatty liver disease in the US population

  2020cites this paper
• Long non-coding RNA Gm12664 up-regulates CAV1 expression to promote hepatocellular lipid accumulation by sponging miR-295-5p

  2020cites this paper
• Liver stiffness as measured by two-dimensional shear wave elastography overestimates the stage of fibrosis in patients with chronic hepatitis B and hepatic steatosis.

  2020cites this paper
• The effects of crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled study

  2020cites this paper
• Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease.

  2019cites this paper
• Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study

  2019cites this paper